Treatment of Disease with Proteasone Inhibitors

• US 20110189204A1
• Filed: 10/01/2010
• Published: 08/04/2011
• Est. Priority Date: 10/01/2009
• Status: Abandoned Application

• Current Assignee: Helgi Van De Velde, Martine Bayssas, Roland D.E. Coster
• Original Assignee: Helgi Van De Velde, Martine Bayssas, Roland D.E. Coster
• Inventors: Van de Velde, Helgi, De Coster, Roland, Bayssas, Martine
• Application Number:
  US12/896,289
• Publication Number:
  US 20110189204A1
• Time in Patent Office: Days
• US Class Current: 424/174.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method is provided for treating cancer in a patient comprising administering to said patient a proteasome inhibitor at least three days a week.

Claims

1. A method for treating cancer in a patient, comprising administering to said patient multiple doses of a proteasome inhibitor, wherein said multiple doses are administered more frequently than every 72 hours or at least three days a week.

2. The method of claim 1, wherein said proteasome inhibitor is administered at least four days a week.

3. The method of claim 2, wherein said proteasome inhibitor is administered at least five days a week.

4. The method of claim 3, wherein said proteasome inhibitor is administered at least six days a week.

5. The method of claim 4, wherein said proteasome inhibitor is administered at least once daily.

6. The method of claim 1, wherein said multiple doses are administered at least once every 48 hours.

7. The method of claim 6, wherein said multiple doses are administered at least once every 24 hours.

8. The method of any one of claims 1-7, wherein said multiple doses are administered for at least two weeks.

9. The method of claim 8, wherein said multiple doses are administered for at least four weeks.

10. The method of any one of claims 1-9, wherein said proteasome inhibitor is administered intravenously, subcutaneously, parenterally, intramuscularly, intradermally, or transdermally.

11. The method of any one of claims 1-10, wherein said proteasome inhibitor is bortezomib.

12. The method of any one of claims 1-10, wherein said cancer is a solid tumor.

13. The method of claim 12, wherein said solid tumor is selected from the group consisting of tumors of the skin, lung, bronchus, prostate, breast, pancreas, adrenal gland, small intestine, large intestine, colon, rectum, thyroid, stomach, liver, bile duct, kidney, renal pelvis, urinary bladder, uterus, cervix, ovary, esophagus, brain, head and neck, oral cavity, pharynx, and larynx

14. The method of any one of claims 1-13, further comprising administering to said patient a second anti-cancer treatment.

15. The method of claim 14, wherein said second anti-cancer treatment is selected from the group consisting of antibody therapy, hormone therapy, radiation, chemotherapy surgery, gene therapy, immunotherapy or other treatments for preventing, treating or ameliorating cancers.

16. The method of claim 15, wherein said chemotherapy is selected from the group consisting of an anti-angiogenic agent, an anti-tumor agent, a cytotoxic agent, and an inhibitor of cell proliferation.

17. The method of any one of claims 1-16, wherein said cancer is refractory or recurrent.

18. The use of a proteasome inhibitor for treatment of cancer wherein said proteasome inhibitor is administered to a patient in need thereof at least three times a week or more frequently than every 72 hours.